Grufity logo
Grufity logo

Latest Sofinnova Investments, Inc. Stock Portfolio

$2.63Billion– No. of Holdings #61

Sofinnova Investments, Inc. Performance:
2026 Q1: -0.65%YTD: -0.65%2025: 43.58%
Performance for 2026 Q1 is -0.65%, and YTD is -0.65%, and 2025 is 43.58%.

About Sofinnova Investments, Inc. and 13F Hedge Fund Stock Holdings

On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Sofinnova Investments, Inc. reported an equity portfolio of $2.6 Billions as of 31 Mar, 2026.

The top stock holdings of Sofinnova Investments, Inc. are NTRA, BMY, JAZZ. The fund has invested 11.8% of it's portfolio in NATERA INC and 4.6% of portfolio in BRISTOL-MYERS SQUIBB CO.

The fund managers got completely rid off ASTRAZENECA PLC (AZN), VERTEX PHARMACEUTICALS INC (VRTX) and ABBVIE INC (ABBV) stocks. They significantly reduced their stock positions in PRAXIS PRECISION MEDICINES INC (PRAX), BRIDGEBIO PHARMA INC (BBIO) and COMPASS THERAPEUTICS INC (CMPX). Sofinnova Investments, Inc. opened new stock positions in ASTRAZENECA PLC, BIOGEN INC (BIIB) and GENMAB A/S (GMAB). The fund showed a lot of confidence in some stocks as they added substantially to ULTRAGENYX PHARMACEUTICAL INC (RARE), AXSOME THERAPEUTICS INC. (AXSM) and XENON PHARMACEUTICALS INC (XENE).
Sofinnova Investments, Inc. Equity Portfolio Value
Last Reported on: 15 May, 2026

Sofinnova Investments, Inc. Annual Return Estimates Vs S&P 500

Our best estimate is that Sofinnova Investments, Inc. made a return of -0.65% in the last quarter. In trailing 12 months, it's portfolio return was 58.27%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
astrazeneca plc89,938,400
biogen inc42,078,100
genmab a/s20,183,200
stryker corporation14,615,700
oric pharmaceuticals inc8,610,250
tango therapeutics inc8,265,100
tyra biosciences inc7,813,780
axogen inc6,979,330
New stocks bought by Sofinnova Investments, Inc.

Additions

Ticker% Inc.
ultragenyx pharmaceutical inc3,676
axsome therapeutics inc.1,634
xenon pharmaceuticals inc409
insmed inc120
alcon ag119
supernus pharmaceuticals72.54
rhythm pharmaceuticals inc65.85
bristol-myers squibb co31.44
Additions to existing portfolio by Sofinnova Investments, Inc.

Reductions

Ticker% Reduced
praxis precision medicines inc-49.35
bridgebio pharma inc-43.2
compass therapeutics inc-38.9
jazz pharmaceuticals plc-37.67
roivant sciences ltd-34.93
disc medicine inc-29.45
dyne therapeutics inc-27.52
arcus biosciences inc-15.83
Sofinnova Investments, Inc. reduced stake in above stock

Sold off

Ticker$ Sold
astrazeneca plc-150,060,000
centessa pharmaceuticals plc-27,617,900
avidity biosciences inc-53,745,200
apogee therapeutics inc-40,370,100
amylyx pharmaceuticals inc-6,367,360
abbvie inc-72,610,200
glaukos corp-32,532,500
cidara therapeutics inc-39,818,700
Sofinnova Investments, Inc. got rid off the above stocks

Sector Distribution

Sofinnova Investments, Inc. has about 79.6% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare79.6
Others20.4

Market Cap. Distribution

Sofinnova Investments, Inc. has about 43.3% of it's portfolio invested in the large-cap and mega-cap stocks.

  • LARGE-CAP
  • MID-CAP
  • UNALLOCATED
  • SMALL-CAP
Category%
LARGE-CAP43.3
MID-CAP27.9
UNALLOCATED20.4
SMALL-CAP8.1

Stocks belong to which Index?

About 41.4% of the stocks held by Sofinnova Investments, Inc. either belong to S&P 500 or RUSSELL 2000 index.

  • Others
  • RUSSELL 2000
  • S&P 500
Index%
Others58.5
RUSSELL 200031.3
S&P 50010.1
Top 5 Winners (%)%
NKTR
nektar therapeutics
62.3 %
bioage labs inc
32.2 %
EWTX
edgewise therapeutics inc
25.4 %
ROIV
roivant sciences ltd
22.8 %
UTHR
united therapeutics corp
21.5 %
Top 5 Winners ($)$
UTHR
united therapeutics corp
16.8 M
JAZZ
jazz pharmaceuticals plc
14.8 M
NKTR
nektar therapeutics
14.1 M
BMY
bristol-myers squibb co
11.7 M
bioage labs inc
9.8 M
Top 5 Losers (%)%
WVE
wave life sciences ltd
-55.3 %
IKNA
imagenebio inc
-27.5 %
BOLT
bolt biotherapeutics inc
-26.1 %
SLNO
soleno therapeutics inc
-26.1 %
NXTC
nextcure inc
-24.7 %
Top 5 Losers ($)$
NTRA
natera inc
-45.1 M
VERA
vera therapeutics inc
-29.1 M
RYTM
rhythm pharmaceuticals inc
-7.2 M
inhibrx biosciences inc
-5.1 M
RARE
ultragenyx pharmaceutical inc
-3.3 M

Sofinnova Investments, Inc. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Sofinnova Investments, Inc.

Sofinnova Investments, Inc. has 61 stocks in it's portfolio. About 42% of the portfolio is in top 10 stocks. NTRA proved to be the most loss making stock for the portfolio. UTHR was the most profitable stock for Sofinnova Investments, Inc. last quarter.

Last Reported on: 15 May, 2026
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions